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Joseph Delano F. Robles, Daniel Ka Leung Cheuk, Shau Yin Ha, Alan Kwok Shing Chiang,
Godfrey Chi Fung ChanNorovirus infections are increasingly being recognized as important causes of diarrhea in hematopoietic
stem cell transplantation (HSCT) recipients. This retrospective study aimed to evaluate the cumulative in-
cidence, risk factors, and outcomes of norovirus infection in pediatric HSCTrecipients. Among 55 patients
age\21 years who underwent first HSCT between July 2007 and June 2011, 49 patients developed diarrhea
and had stool tested for norovirus. Eight of these patients were found to be infected with norovirus. All were
sporadic cases and manifested with nausea, vomiting, and diarrhea. The median age of these patients was 5.2
years (range, 0.5-18.5 years). Six were males. Seven patients underwent unrelated donor HSCT, and 1 patient
underwent autologous cord blood HSCT. Two patients had norovirus infection before HSCT that persisted
after transplantation. In the remaining 6 patients, norovirus developed at a median of 36.5 days posttransplan-
tation (range, 5-517 days). The cumulative incidence of norovirus infection was 12.9% at 2 years posttrans-
plantation. Risk factors for norovirus infection included the use of peripheral blood or cord blood as the stem
cell source (P5 .043) and administration of fludarabine (P5 .002) and alemtuzumab (P5 .011). The median
time to viral clearance was 145 days (range, 13-263 days). Four-year survival was similar in norovirus-infected
patients and noninfected patients (56.3% versus 58.3%).
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Hematopoietic stem cell transplantation (HSCT)
is an effective treatment modality for both malignant
and nonmalignant disorders. However, infections after
HSCT are quite common, given the patient’s immuno-
compromised state as a result of conditioning che-
motherapy and immunosuppressant therapy; other
procedures before HSCT, such as T cell depletion,
donor–recipient histocompatibility mismatch, infections
before HSCT, graft-versus-host disease (GVHD),
immunosuppressive medications given for GVHD, and
prolongedhospitalization can cause exposure to amyriad
of bacterial, viral, and fungal infections.Department of Paediatrics and Adolescent Medicine,
n Mary Hospital, University of Hong Kong, Hong Kong.
isclosure: See Acknowledgments on page 1888.
dence and reprint requests: Godfrey Chi Fung Chan, De-
ent of Paediatrics and Adolescent Medicine, Queen Mary
ital, Li Ka Shing Faculty of Medicine, University of Hong
, Hong Kong (e-mail: gcfchan@hkucc.hku.hk).
ay 17, 2012; accepted July 5, 2012
erican Society for Blood and Marrow Transplantation
/$36.00
oi.org/10.1016/j.bbmt.2012.07.005Norovirus is a genus of single-stranded RNA virus
belonging to the family Caliciviridae [1]. Norovirus
was formerly known as Norwalk-like virus, because it
caused an outbreak in Norwalk, Ohio in 1968 [2].
The virus was further characterized by Kapikian
et al. [3] in 1972 in their experiments using the agent
associated with the Norwalk outbreak. Norovirus is
now recognized as a common cause of outbreaks of
nonbacterial gastroenteritis in schools, nursing homes,
day care centers, and hospitals worldwide [4-9]. It also
has been identified as a common cause of sporadic
gastroenteritis in many community-based studies [9].
Intestinal infection is a common cause of diarrhea
in HSCT recipients [10,11]. Adenovirus and rotavirus
have been reported as important etiologic agents [12].
Viruses may cause mucosal damage, increasing
patients’ vulnerability to infection by intestinal bacteria,
and hence these patients require close monitoring [13].
Norovirus can cause significant morbidity and even
mortality in immunocompromised hosts, including
solid organ transplant recipients [14-17]. The
occurrence of norovirus infection in HSCT recipients
is being increasingly recognized. Case reports include
a child who had prolonged symptoms and norovirus
shedding after HSCT for cartilage hair hypoplasia [18]1883
1884 Biol Blood Marrow Transplant 18:1883-1889, 2012J. D. F. Robles et al.and amiddle-age womanwith norovirus infection after-
doubleHSCTand lung transplantation [19].Retrospec-
tive case series on norovirus gastroenteritis in adult [20]
and pediatric recipients of HSCT [21] have been re-
ported; however, the incidenceofnorovirus gastroenter-
itis in HSCT recipients has not been described, with no
denominator data provided, and the risk factors associ-
ated with norovirus infection in HSCT recipients have
not been systematically studied.
In Hong Kong, norovirus is a common cause of
gastroenteritis in children. Sporadic cases and out-
breaks occur throughout the year, with peaks usually
in winter months [22], as in many other countries [9].
The present study aimed to evaluate the cumulative in-
cidence of norovirus gastroenteritis in pediatric
HSCT recipients, the risk factors for norovirus infec-
tion, and its outcomes.PATIENTS AND METHODS
Study Design
This study was a retrospective review of the clinical
records and electronic database of children age\21
years who underwent a first HSCT in our unit over
the past 4 years (July 2007 to June 2011). The clinical
characteristics of these patients, and outcomes of pa-
tients who had norovirus infection, were described,
and risk factors associated with development of noro-
virus gastroenteritis were analyzed.
Transplantation Method
The choice of stem cell source between bone mar-
row and peripheral blood stem cells (PBSCs) for
matched unrelated donor transplants depended largely
on the preference of the donor. Cord blood that was
5/6 or 6/6 HLA-matched was preferred if an HLA-
matched sibling donor or an 8/8 HLA-matched unre-
lated donor was not available. Antifungal prophylaxis
with fluconazole was given to all patients during the
first 30 days after transplantation or continued until
weaning of immunosuppressive therapy. Acyclovir
and cotrimoxazole were used during the first 6 months
and was continued in patients who remained on immu-
nosuppressant therapy. Preemptive cytomegalovirus
(CMV) therapy with either ganciclovir or foscarnet
was adopted, with monitoring by CMV-PCR and
pp65 antigenemia. Immunoglobulin was not given
routinely.
Evaluation for Diarrhea and Norovirus
Diarrhea was defined as passage of loose to watery
stool at least 3 times within 24 hours, with nominimum
number of days required to qualify. Stool specimens
obtained from patients experiencing diarrhea were
typically tested for bacterial pathogens, Clostridiumdifficile, viral culture, and ELISA for rotavirus. Norovi-
rus testing was done by RT-PCR in the central govern-
ment virology laboratory in Hong Kong following
a method adopted from Kageyama et al. [23]. Genotyp-
ing and analysis of viral loads were not done. Not all
episodes of diarrhea in all patients were tested for all
these pathogens, with testing left to the discretion of
the clinician.Thedurationof viruspositivitywasdefined
as the date of the first positive norovirus test to the date
of the last positive norovirus test. The duration of virus
clearance was defined as the date of the first positive
norovirus test to the date of the first negative norovirus
test. The difference between the 2 durations was the
time between the last positive test and the first negative
test. Chronic GVHD was diagnosed according to
National Institutes of Health consensus criteria [24].Statistical Analysis
The cumulative incidence of norovirus infection
after HSCT and overall survival rate were estimated
by the Kaplan-Meier method. The c2 test was used
to assess the significance of potential risk factors for
norovirus infection. Multivariate analysis was not
done because of the small sample size. A P value
\.05 for a 2-tailed test was considered statistically sig-
nificant. All analyses were performed using SPSS ver-
sion 15.0 (SPSS, Inc., Chicago, IL).RESULTS
Incidence, Characteristics, and Outcomes of
Norovirus Infection
A total of 55 first HSCTs were performed during
the study period. The median patient age at transplan-
tation was 9.0 years (range, 0.7-20.6 years). Transplant
characteristics are summarized in Table 1. Six patients
did not have diarrhea and thus had no stools tested for
diarrheal pathogens. The infective causes of diarrhea
in the remaining 49 patients are listed in Table 2. All
these 49 patients were tested for norovirus, 8 of
whom (16.3%) were positive. In 5 patients, norovirus
infection was community-acquired outside of the hos-
pital. In the remaining 3 patients, infection was ac-
quired after hospitalization for more than 3 days;
however, whether these infections were transmitted
from another patient, a healthcare worker, a visitor,
or food or water is unclear. All 8 norovirus infections
were sporadic and did not occur in outbreak situations.
The median age of these 8 patients at time of HSCT
was 5.2 years (range, 0.8-18.5 years). Six of them
were males. Their diagnoses and transplant character-
istics are summarized in Table 3.
In 2 of the 8 patients with norovirus infection, in-
fection occurred before HSCT and persisted after
transplantation. Six patients acquired norovirus
Table 2. Infective Causes of Diarrhea in Recipients of First
HSCT between July 2007 and June 2011
Organism(s) Number %
Norovirus 4 8.2
Norovirus + Clostridium difficile* 4 8.2
C difficile 14 28.6
Salmonella group C 1 2.0
Salmonella group C + C difficile† 1 2.0
Salmonella group E + C difficile + Adenovirus† 1 2.0
Adenovirus 1 2.0
Adenovirus + C difficile† 1 2.0
Rotavirus 1 2.0
No infective organisms identified 21 42.9
Total 49 100
*These infections occurred concurrently.
†These infections occurred at different times.
Table 1. Characteristics of All Recipients of First HSCT
between July 2007 and June 2011
Characteristic Number %
Sex
Male 33 60.0
Female 22 40.0
Underlying disease
Acute leukemia 19 34.5
Myeloproliferative neoplasm or myelodysplastic
syndrome
4 7.3
Lymphoma 2 3.6
Solid tumor 11 20.0
Thalassemia 15 27.3
Others 4 7.3
Type of transplant
Autologous 12 21.8
Allogeneic 43 78.2
Type of donor
Autologous 12 21.8
Matched sibling 8 14.5
Mismatched sibling 1 1.8
Matched unrelated donor 20 36.5
Mismatched unrelated donor 14 25.5
Stem cell source
Bone marrow 20 36.4
Peripheral blood stem cell 16 29.1
Cord blood 19 34.5
Conditioning
Busulfan + cyclophosphamide +/2 others 32 58.2
Total body irradiation-based regimen 8 14.5
Fludarabine-based regimen 3 5.5
Etoposide or teniposide + adriamycin + melphalan +
cisplatin (VAMP)
7 12.7
Thiotepa + etoposide + carboplatin 3 5.5
Carmustine + etoposide + cytarabine + melphalan
(BEAM)
1 1.8
Etoposide + melphalan 1 1.8
Graft-versus-host disease prophylaxis
Anti–thymocyte globulin + cyclosporine A +
methotrexate +/2 others
17 39.5
Alemtuzumab + cyclosporine A +/2 others 4 9.3
Cyclosporin A + methotrexate 16 37.2
Cyclosporin A + mycophenolate mofetil 5 11.6
Tacrolimus + mycophenolate mofetil 1 2.3
Biol Blood Marrow Transplant 18:1883-1889, 2012 1885Norovirus Infection in Pediatric HSCT Recipientsinfection after HSCT. The cumulative incidence of
norovirus infection was estimated as 7.5% at 6 months
and 12.9% at 2 years posttransplantation (Figure 1).
For the 6 patients who acquired norovirus after
HSCT, the infection occurred at a median of 36.5
days posttransplantation (range, 5-517 days). Six of
the 8 patients had received or were receiving multipleTable 3. Transplant Characteristics in Patients with Norovirus Infe
Patient Sex
Age at HSCT,
Years Primary Disease
Type of
Transplant
1 Male 18.5 AML in second remission Allogeneic
2 Male 1.7 Neuroblastoma stage 4 Autologous
3 Male 0.8 Infant ALL in first remission Allogeneic
4 Male 9.0 Thalassemia major Allogeneic
5 Male 10.5 Severe aplastic anemia Allogeneic
6 Male 1.0 Severe congenital
neutropenia
Allogeneic
7 Female 0.8 Infant ALL in first remission Allogeneic
8 Female 8.8 Thalassemia major Allogeneic
ATG indicates antithymocyte globulin; ALL, acute lymphoblastic leukemia; AML
cyclosporine A; Flu, fludarabine; Mel, melphalan; MMF, mycophenolate mofe
matched unrelated donor; TBI, total body irradiation; VAMP, teniposide + adrimmunosuppressants at the time of infection (Table 4).
Six patients had other infections documented, includ-
ing 4 patients with concurrentC difficile infection and 2
patients with concurrent CMV infection. All 4 patients
infected with C difficile were treated with appropriate
antibiotics with clearance of C difficile; however, diar-
rheal symptoms persisted in all of these patients.
Six patients had acute GVHD (aGVHD), 3 before
and 3 after the onset of norovirus infection. Only pa-
tient 2, who received an autologous transplant, and pa-
tient 5, who failed engraftment, did not have acute
GVHD. The association between norovirus infection
and aGVHD was not statistically significant, however
(P 5 .35). In contrast, norovirus infection was signifi-
cantly associated with chronic GVHD (P 5 .036).
Two patients had concurrent chronic GVHD at the
time of norovirus infection, and 3 patients developed
chronic GVHD (cGVHD) after norovirus infection.
The median duration of viral positivity in stool was
135.5 days (range, 4-247 days). The median time to
clearance of the virus was 145 days (range, 13-263
days). Six of the 8 patients with norovirus infection
were wasted and required total parenteral nutrition.
Three patients died, 1 of whom still carried the virus
with persistent diarrhea at the time of death. Overall
survival at 4 years was similar in patients with norovi-
rus infection and those without norovirus infection
(56.3% versus 58.3%) (Figure 2).ction
Donor Stem Cell Source Conditioning GVHD Prophylaxis
MMUD PBSC Flu/Bu/TBI CyA/MMF
Autologous Cord blood VAMP None
MMUD PBSC Bu/Cy/Mel ATG/CyA/MTx
MUD PBSC Bu/Cy ATG/CyA/MTx
MMUD Cord blood Flu/Cy Alemtuzumab/CyA
MMUD Cord blood Flu/Cy Alemtuzumab/CyA/MTx
MMUD Cord blood Bu/Cy/Mel CyA/MMF
MUD PBSC Bu/Cy ATG/CyA/MTx
, acute myelogenous leukemia; Bu, busulfan, Cy, cyclophosphamide; CyA,
til; MMUD, mismatched unrelated donor; MTx, methotrexate; MUD,
iamycin + melphalan + cisplatin.
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Figure 1. Cumulative incidence of norovirus infection after HSCT.
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Results of analyses of risk factors for norovirus
infection after HSCT are shown in Table 5. The 2 pa-
tients who had norovirus infection before HSCT were
excluded from these analyses. We found that patients
who received stems cells from PBSCs or cord blood
were more likely to develop norovirus infection com-
pared with those who received stem cells from bone
marrow. Patients who had a received fludarabine-
based conditioning regimen were also more likely to
develop norovirus infection compared with those
receiving other conditioning regimens. Patients who
had received alemtuzumab were also at significantly
greater risk of norovirus infection.DISCUSSION
Norovirus is a common cause of gastroenteritis
that is being increasingly reported in immunocompro-
mised patients, including HSCT recipients. A retro-
spective study on norovirus gastroenteritis in 12
adult recipients of allogeneic HSCT [20] and a case se-
ries on chronic norovirus infection in 13 pediatric
HSCT recipients [21] have been published. The inci-
dence of norovirus infection in HSCT recipients has
not yet been reported, however. Here we report the
second study on norovirus infection in pediatric
HSCT recipients, in which we found a cumulative
incidence of norovirus of .10%. This is a minimum
estimate, given that our patients who did not have
diarrhea (and thus were not tested for norovirus) also
might have harbored norovirus, and not all episodes
of diarrhea were tested for norovirus. Norovirus infec-
tion tends to develop within the first few months after
HSCT, when the patient is the most immunocompro-
mised. In a case series reported by Saif et al. [21], 13 pe-
diatric HSCT recipients developed norovirus at 17-63
days posttransplantation. We found that norovirus
also can occur later, especially in patients who remain
severely immunocompromised with chronic GVHDrequiring immunosuppressive therapy. This was also
the case in the adult series reported by Roddie et al.
[20], in which 4 of the 12 patients developed norovirus
beyond 1 year posttransplantation. Therefore, norovi-
rus infection needs to be considered even in patients
who develop diarrhea late after HSCT.
All 8 of our patients infected with norovirus were
symptomatic, and most had quite prolonged viral excre-
tion. Their median time to viral clearance was similar to
that reportedbySaif et al. [21] (145days versus 150days),
but longer than that reported by Schwartz et al. [25] in 6
oncology patients and 5HSCT recipients (36 days), and
that reportedbyLudwig et al. [26] in 7 oncology patients
and 2 HSCT recipients (57 days). The median duration
of viral positivitywas also longer in our cohort compared
with that reported by Simon [27] (23 days), Schwartz
et al. [25] (30 days), and Ludwig et al. [26] (38 days).
These results suggest that the duration of viral carriage
is closely related to the duration of immunosuppression,
which is generally longer inHSCT recipients compared
with other oncology patients.
The risk factors for norovirus infection in HSCT
recipients have not been reported previously. We
found that certain transplant characteristics were asso-
ciated with a significantly higher risk of norovirus in-
fection. For example, patients who received PBSCs
or cord blood were at increased risk of posttransplan-
tation norovirus infection compared with those who
received bone marrow. This may be because PBSC
transplant is associated with greater risk of acute and
chronic GVHD [28,29], which are associated with
heavy immunosuppression due either to GVHD
itself or the use of potent immunosuppressants. We
found that norovirus gastroenteritis occurred in close
association with GVHD, similar to the case series
reported by Roddie et al. [20], in which 9 of the 12
norovirus-infected patients had GVHD. On the other
hand, cord blood transplant is associated with im-
paired cellular immunity in the early posttransplanta-
tion period compared with bone marrow transplant,
leading to a heightened risk of infection [30]. In addi-
tion, we found that use of the potent immunosuppres-
sants fludarabine and alemtuzumab was also
significantly associated with posttransplantation noro-
virus infection. All of these findings support the essen-
tial role of host immunity in protection against
norovirus infection. The presence and persistence of
norovirus infection can be considered a marker of
heavy immunosuppression. In fact, the study by Saif
et al. [21] demonstrated that norovirus clearance is
closely associated with T cell recovery.
The present risk factor analysis has some limita-
tions. The identified risk factors might represent those
associated with the development of prolonged disease
rather than just the development of infection, given
that all episodes of diarrhea were investigated for nor-
ovirus and the triggers for testing were variable and
Table 4. Associated Features of Norovirus Infection and Outcome
Patient
Onset of
Norovirus
Infection after
HSCT, Days
Duration of
Norovirus
Positivity,
Days
Time to
Norovirus
Clearance,
Days
Duration of
Diarrhea,
Days
TPN
Required
Acute GVHD
Grade Chronic GVHD Additional Drugs*
Other Post-HSCT
Infections Outcome
1 417 247 263 Wax and
wane
Yes III (skin, gut)† Yes† (lung‡, skin§,
oral§, gut¶)
Steroid, infliximab,
antithymocyte globulin
Bacillus, Mycobacterium
chelonae, Pseudomonas
aeruginosa, Aspergillus
fumigatus, Aspergillus
terreus, Enterobacter,
Enterococcus, Clostridium
difficile, Candida albicans,
RSV, CMV
Died of GVHD and
infections
2 63 93 100 45 Yes No No None Aeromonas caviae,
Clostridium difficile,
influenza B
Alive
3 2151** 175 197 124 Yes III†† (skin,
liver, gut)
Yes†† (lung‡,
skin§, oral§)
Steroid, infliximab MSSA, Clostridium difficile,
influenza A, parainfluenza
Alive
4 5 29 43 29 Yes III†† (skin, gut) Yes†† (skin§,
gut¶, liver¶)
Steroid, mycophenolate
mofetil
Alive
5 10 4 13 12 No No No None Died of graft failure
6 10 134 153 113 Yes II†(skin) Yes†† (skin§) Steroid Clostridium difficile, CMV Alive
7 271** >137‡‡ >137‡‡ 137 Yes III††(skin,
liver, gut)
No Steroid, infliximab Acinetobacter baumanii Died of idiopathic
pneumonia
8 517 >169§§ >169§§ Wax and
wane
No III†(skin, gut) Yes†† (lung‡, skin§,
oral§, gut¶)
Steroid, tacrolimus Candida albicans, RSV,
parainfluenza
Alive
MSSA indicates methicillin-sensitive Staphylococcus aureus; RSV, respiratory syncytial virus; TPN, total parenteral nutrition.
*Immunosuppressants received in addition to those used for GVHD prophylaxis before and during norovirus infection.
†GVHD developed before onset of norovirus infection.
‡Distinctive features of cGVHD were present but insufficient for definitive diagnosis.
§Diagnostic signs of cGVHD were present.
¶Common features of cGVHD were present.
**Norovirus infection was documented before HSCT.
††GVHD developed after onset of norovirus infection.
‡‡This patient died with persistent positive Norovirus RT-PCR in stool. The number represents the time between initial detection of norovirus infection and the death of the patient.
§§This patient still had a positive test for Norovirus RT-PCR at the time of this report.
B
io
l
B
lo
o
d
M
a
rro
w
T
ra
n
sp
la
n
t
1
8
:1
8
8
3
-1
8
8
9
,
2
0
1
2
1
8
8
7
N
o
ro
viru
s
In
fe
ctio
n
in
P
e
d
ia
tric
H
S
C
T
R
e
cip
ie
n
ts
0 1 2 3 4 5
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Norovirus negative
Norovirus positive
Time (years after HSCT)
O
v
e
r
a
l
l
 
s
u
r
v
i
v
a
l
Figure 2. Overall survival in HSCT recipients with and without noro-
virus infection.
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immunosuppressed patients had been able to clear
their infection, then detection of infection might
have been less likely in this group. The more immuno-
suppresed patients may not be at greater risk of devel-
oping norovirus infection, but if it develops, it is more
likely to be prolonged or persistent and thus detected.
In addition, we did not perform multivariate analysis
owing to our small sample size, and whether the risk
factors are independent of one another is unclear.
In the report bySchwartz et al. [25], norovirus infec-
tion was lethal in 2 of the 5 adult HSCT recipients, due
to bowel perforation and aspiration pneumonia. One of
the 12 adult transplant recipients reported by Roddie
et al. [20] died of malnutrition due to norovirus infec-
tion. However, we did not observe increased mortality
among HSCT recipients who had developed norovirus
infection compared with uninfected recipients.
Diarrhea is a common problem during the post-
transplantation period [31], and multiple intestinalTable 5. Analysis of Potential Risk Factors for Norovirus
Infection
Risk Factor Odds Ratio P Value
Sex
Male versus female 3.70 .22
Underlying disease
Malignancy versus nonmalignant conditions 0.23 .10
Type of transplant
Allogeneic versus autologous 1.53 .71
Type of donor
Unrelated donor versus family donors 3.8 .21
HLA-mismatched donor versus
HLA-matched donor
3.9 .15
Stem cell source
PBSC or cord blood versus bone marrow 9.69 .043
Conditioning
Fludarabine-containing regimen versus others 23.00 .002
Total body irradiation–containing regimen
versus others
1.18 .88
GVHD prophylaxis
Antithymocyte globulin–containing regimen
versus others
2.62 .26
Alemtuzumab-containing regimen
versus others
11.25 .011infections and GVHD often coexist. We also found
a common coexistence of norovirus with other intestinal
infections, such as C difficile. Therefore, we recommend
performing multiple microbiological investigations, in-
cluding norovirus RT-PCR, in patients who experience
diarrhea after HSCT, even those with suspected or
confirmed gastrointestinal GVHD. There is no proven
effective antiviral treatment for norovirus infection,
although a recent report suggested possible efficacy of
nitazoxanide [32]. Management of norovirus infection
is still mainly supportive and involves meticulous atten-
tion tofluid and electrolyte balance. Proper cohorting of
patients, hand hygiene, and other infection controlmea-
sures to prevent outbreak are of paramount importance.
In conclusion, norovirus infection is the secondmost
common cause (after C difficile) of infectious diarrhea in
pediatric recipients of HSCT and should be considered
in posttransplantation patients with diarrhea. It is associ-
ated with both acute and chronic GVHD, as well as the
use of multiple-immunosuppressant therapy. Peripheral
blood or cord blood as the stem cell source and the use
of fludarabine or alemtuzumab are significant risk fac-
tors. Morbidity can be significant, and viral excretion is
often prolonged in these severely immunocompromised
patients. Meticulous supportive care and infection con-
trol are essential.ACKNOWLEDGMENTS
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